Oncolytic adenovirus encoding decorin and CD40 ligand for triple-negative breast cancer immunotherapy
This study evaluated an oncolytic adenovirus co-expressing decorin (DCN) and CD40 ligand (CD40L), designated rAd.DCN.CD40L, for its antitumor activity and immune activation against triple-negative breast cancer (TNBC).